Suppr超能文献

不同腺相关病毒血清型与合成肝素及其他聚糖的特异性相互作用模式。

Differential adeno-associated virus serotype-specific interaction patterns with synthetic heparins and other glycans.

作者信息

Mietzsch Mario, Broecker Felix, Reinhardt Anika, Seeberger Peter H, Heilbronn Regine

机构信息

Institute of Virology, Campus Benjamin Franklin, Charité Medical School, Berlin, Germany.

出版信息

J Virol. 2014 Mar;88(5):2991-3003. doi: 10.1128/JVI.03371-13. Epub 2013 Dec 26.

Abstract

All currently identified primary receptors of adeno-associated virus (AAV) are glycans. Depending on the AAV serotype, these carbohydrates range from heparan sulfate proteoglycans (HSPG), through glycans with terminal α2-3 or α2-6 sialic acids, to terminal galactose moieties. Receptor identification has largely relied on binding to natural compounds, defined glycan-presenting cell lines, or enzyme-mediated glycan modifications. Here, we describe a comparative binding analysis of highly purified, fluorescent-dye-labeled AAV vectors of various serotypes on arrays displaying over 600 different glycans and on a specialized array with natural and synthetic heparins. Few glycans bind AAV specifically in a serotype-dependent manner. Differential glycan binding was detected for the described sialic acid-binding AAV serotypes 1, 6, 5, and 4. The natural heparin binding serotypes AAV2, -3, -6, and -13 displayed differential binding to selected synthetic heparins. AAV7, -8, -rh.10, and -12 did not bind to any of the glycans present on the arrays. For discrimination of AAV serotypes 1 to 6 and 13, minimal binding moieties are identified. This is the first study to differentiate the natural mixed heparin binding AAV serotypes 2, 3, 6, and 13 by differential binding to specific synthetic heparins. Also, sialic acid binding AAVs display differential glycan binding specificities. The findings are relevant for further dissection of AAV host cell interaction. Moreover, the definition of single AAV-discriminating glycan binders opens the possibility for glycan microarray-based discrimination of AAV serotypes in gene therapy.

摘要

目前已鉴定出的所有腺相关病毒(AAV)的主要受体都是聚糖。根据AAV血清型的不同,这些碳水化合物的范围从硫酸乙酰肝素蛋白聚糖(HSPG),到带有末端α2-3或α2-6唾液酸的聚糖,再到末端半乳糖部分。受体的鉴定主要依赖于与天然化合物、特定的聚糖呈递细胞系或酶介导的聚糖修饰的结合。在此,我们描述了对多种血清型的高度纯化、荧光染料标记的AAV载体在展示600多种不同聚糖的阵列以及含有天然和合成肝素的特殊阵列上进行的比较结合分析。很少有聚糖以血清型依赖的方式特异性结合AAV。在所描述的唾液酸结合型AAV血清型1、6、5和4中检测到了不同的聚糖结合情况。天然肝素结合型血清型AAV2、-3、-6和-13对选定的合成肝素表现出不同的结合情况。AAV7、-8、-rh.10和-12不与阵列上存在的任何聚糖结合。对于区分AAV血清型1至6和13,确定了最小结合部分。这是第一项通过与特定合成肝素的差异结合来区分天然混合肝素结合型AAV血清型2、3、6和13的研究。此外,唾液酸结合型AAV显示出不同的聚糖结合特异性。这些发现对于进一步剖析AAV与宿主细胞的相互作用具有重要意义。此外,单一AAV区分性聚糖结合剂的定义为基于聚糖微阵列的基因治疗中AAV血清型的区分提供了可能性。

相似文献

引用本文的文献

1
Are viral vector-mediated therapies compatible with aberrant glycosylation?病毒载体介导的疗法与异常糖基化相容吗?
Mol Ther Methods Clin Dev. 2025 Jul 22;33(3):101540. doi: 10.1016/j.omtm.2025.101540. eCollection 2025 Sep 11.
7
Neurosurgical gene therapy for central nervous system diseases.神经外科基因治疗中枢神经系统疾病。
Neurotherapeutics. 2024 Jul;21(4):e00434. doi: 10.1016/j.neurot.2024.e00434. Epub 2024 Aug 26.
9
Mechanisms and Delivery of tRNA Therapeutics.tRNA 治疗药物的作用机制与递送。
Chem Rev. 2024 Jun 26;124(12):7976-8008. doi: 10.1021/acs.chemrev.4c00142. Epub 2024 May 27.
10
Analysis of Functional NMDA Receptors in Astrocytes.星形胶质细胞中功能性 NMDA 受体的分析。
Methods Mol Biol. 2024;2799:201-223. doi: 10.1007/978-1-0716-3830-9_11.

本文引用的文献

7
AAV capsid structure and cell interactions.腺相关病毒衣壳结构与细胞相互作用。
Methods Mol Biol. 2011;807:47-92. doi: 10.1007/978-1-61779-370-7_3.
10
Applications of heparin and heparan sulfate microarrays.肝素和硫酸乙酰肝素微阵列的应用。
Methods Enzymol. 2010;478:197-218. doi: 10.1016/S0076-6879(10)78009-5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验